[go: up one dir, main page]

CL2021001096A1 - Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196) - Google Patents

Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)

Info

Publication number
CL2021001096A1
CL2021001096A1 CL2021001096A CL2021001096A CL2021001096A1 CL 2021001096 A1 CL2021001096 A1 CL 2021001096A1 CL 2021001096 A CL2021001096 A CL 2021001096A CL 2021001096 A CL2021001096 A CL 2021001096A CL 2021001096 A1 CL2021001096 A1 CL 2021001096A1
Authority
CL
Chile
Prior art keywords
myelodysplastic syndrome
methods
mds
subject
divisional application
Prior art date
Application number
CL2021001096A
Other languages
English (en)
Inventor
Aleksandra Rizo
Jacqueline Cirillo Bussolari
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021001096(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geron Corp filed Critical Geron Corp
Publication of CL2021001096A1 publication Critical patent/CL2021001096A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgación proporciona métodos para tratar un síndrome mielodisplásico (MDS) en un sujeto que no ha recibido tratamiento con un agente seleccionado de un agente de hipometilación (HMA) y lenalidomida, o ambos. El método incluye administrar al sujeto una cantidad eficaz de un inhibidor de la telomerasa, como por ejemplo, el imetelstat o el sodio de imetelstat. En algunos casos, el sujeto tratado se clasifica como con MDS de riesgo bajo/intermedio-1 de IPSS y/o que tiene MDS recidivante/resistente a agente estimulante de la eritropoyesis (ESA).
CL2021001096A 2017-07-28 2021-04-28 Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196) CL2021001096A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538315P 2017-07-28 2017-07-28
US201762595329P 2017-12-06 2017-12-06
US201862685542P 2018-06-15 2018-06-15

Publications (1)

Publication Number Publication Date
CL2021001096A1 true CL2021001096A1 (es) 2021-11-12

Family

ID=63209674

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020000196A CL2020000196A1 (es) 2017-07-28 2020-01-23 Métodos para tratar el síndrome mielodisplásico.
CL2021001096A CL2021001096A1 (es) 2017-07-28 2021-04-28 Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020000196A CL2020000196A1 (es) 2017-07-28 2020-01-23 Métodos para tratar el síndrome mielodisplásico.

Country Status (17)

Country Link
US (1) US12171778B2 (es)
EP (1) EP3658156A1 (es)
JP (4) JP7316261B2 (es)
KR (2) KR20250151565A (es)
CN (2) CN121243203A (es)
AU (2) AU2018307983B2 (es)
BR (1) BR112020001749A2 (es)
CA (1) CA3069010A1 (es)
CL (2) CL2020000196A1 (es)
IL (1) IL272163B1 (es)
MA (1) MA49688A (es)
MX (1) MX2025005894A (es)
SG (1) SG11201913984RA (es)
TW (1) TWI879717B (es)
UA (1) UA127701C2 (es)
WO (1) WO2019023667A1 (es)
ZA (1) ZA202000070B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN121243203A (zh) 2017-07-28 2026-01-02 美国杰龙生物医药公司 治疗骨髓增生异常综合征的方法
CA3120704A1 (en) 2018-11-29 2020-06-04 Geron Corporation Methods of treating myelodysplastic syndrome
KR20230041707A (ko) 2020-07-17 2023-03-24 제론 코포레이션 피하 텔로머라제 억제제 조성물 및 이의 사용 방법

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
EP1210357B1 (en) 1999-09-10 2008-04-02 Geron Corporation Oligonucleotide n3'-p5' thiophosphoramidates: their synthesis and use
WO2001053307A1 (en) 2000-01-21 2001-07-26 Geron Corporation 2'-arabino-fluorooligonucleotide n3'→p5'phosphoramidates: their synthesis and use
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
JP4854913B2 (ja) 2001-03-23 2012-01-18 ジェロン・コーポレーション オリゴヌクレオチド結合体
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
JP4690324B2 (ja) 2003-09-09 2011-06-01 ジェロン・コーポレーション テロメラーゼ阻害のための改変オリゴヌクレオチド
EP1694842B1 (en) 2003-11-04 2011-03-23 Geron Corporation Rna amidates and thioamidates for rnai
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
ME02933B (me) 2004-07-02 2018-04-20 Geron Corp Sinteza zaštićenih 3'-amino nukleozionih monomera
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113426A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
EP1910342A1 (en) 2005-07-29 2008-04-16 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
US7989428B2 (en) 2006-10-30 2011-08-02 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
ES2407957T3 (es) 2007-03-09 2013-06-17 Geron Corporation Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa
WO2008153900A1 (en) 2007-06-06 2008-12-18 University Of Florida Research Foundation Kinase inhibitor compounds
CN101220044B (zh) 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
LT3029154T (lt) 2008-10-17 2017-12-27 Geron Corporation Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas
WO2011017096A2 (en) 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
WO2011098901A1 (en) 2010-02-12 2011-08-18 Ipsogen Asxl1 as a new diagnostic marker of myeloid neoplasms
EP2702168B1 (en) 2011-04-29 2018-01-17 Sequenom, Inc. Quantification of a minority nucleic acid species
US20150005250A1 (en) 2011-10-13 2015-01-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Telomerase reverse transcriptase deficiency as diagnostic marker of myelodysplastic syndrome
WO2013059738A2 (en) 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US9593137B2 (en) 2011-12-22 2017-03-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
EP2925889B1 (en) 2012-11-30 2018-09-05 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
HUE049858T2 (hu) 2012-12-07 2020-11-30 Geron Corp A telomerázgátló imetelstat alkalmazása mielodiszpláziás szindróma kezelésére
US20160022708A1 (en) 2013-03-14 2016-01-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
HRP20190538T1 (hr) 2013-11-06 2019-05-17 Mayo Foundation For Medical Education And Research Postupci i materijali za liječenje hematoloških malignosti
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN121243203A (zh) 2017-07-28 2026-01-02 美国杰龙生物医药公司 治疗骨髓增生异常综合征的方法

Also Published As

Publication number Publication date
BR112020001749A2 (pt) 2020-07-21
KR102867725B1 (ko) 2025-10-13
KR20250151565A (ko) 2025-10-21
IL272163B1 (en) 2025-12-01
AU2018307983A1 (en) 2020-02-13
CL2020000196A1 (es) 2020-11-20
ZA202000070B (en) 2025-09-25
IL272163A (en) 2020-03-31
TW202432146A (zh) 2024-08-16
JP7316261B2 (ja) 2023-07-27
CN121243203A (zh) 2026-01-02
JP2024015000A (ja) 2024-02-01
TW201919705A (zh) 2019-06-01
JP7654761B2 (ja) 2025-04-01
CA3069010A1 (en) 2019-01-31
NZ760873A (en) 2024-03-22
UA127701C2 (uk) 2023-12-06
AU2024219941A1 (en) 2024-10-10
JP2023009229A (ja) 2023-01-19
MA49688A (fr) 2020-06-03
TWI879717B (zh) 2025-04-11
CN110944646A (zh) 2020-03-31
EP3658156A1 (en) 2020-06-03
US20190030064A1 (en) 2019-01-31
JP2020528915A (ja) 2020-10-01
JP2025013669A (ja) 2025-01-24
US12171778B2 (en) 2024-12-24
SG11201913984RA (en) 2020-02-27
JP7654615B2 (ja) 2025-04-01
KR20200033269A (ko) 2020-03-27
WO2019023667A1 (en) 2019-01-31
AU2018307983B2 (en) 2024-07-18
MX2025005894A (es) 2025-06-02

Similar Documents

Publication Publication Date Title
CL2021001096A1 (es) Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2024012816A (es) Metodos para tratar y/o prevenir la enfermedad de injerto contra huesped y/o la hemorragia alveolar difusa y/o la enfermedad venooclusiva asociada al trasplante de celulas madre hematopoyeticas
MX382902B (es) Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
BR112018069220A2 (pt) uso de polipeptídeo que tem atividade de dnase para tratamento de tecidos
ECSP20082339A (es) Moduladores de la expresión de apol1
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
CR20210103A (es) Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
MX2020009147A (es) Moduladores de la expresion de irf4.
MX2019014667A (es) Tratamiento de trastornos cutaneos.
UY38720A (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
CO2021007006A2 (es) Moduladores de la expresión de irf5
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
CL2021001386A1 (es) Métodos de tratamiento del síndrome mielodisplásico
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
CO2020003134A2 (es) Moduladores de la expresión de enac
UY38472A (es) Moduladores de la expresión de foxp3
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
AR112288A1 (es) Métodos para tratar el síndrome mielodisplásico
BR112017016596A2 (pt) composição farmacêutica para prevenir ou tratar a leucemia mieloide crônica, e método de prevenção ou tratamento da leucemia mieloide crônica de um sujeito
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol